✦ LIBER ✦

A Novel Platform for Radioimmunotherapy: Extracorporeal Depletion of Biotinylated and 90 Y-Labeled Rituximab in Patients with Refractory B-Cell Lymphoma

✍ Scribed by Lindén, Ola; Kurkus, Jan; Garkavij, Michael; Cavallin-Ståhl, Eva; Ljungberg, Michael; Nilsson, Rune; Ohlsson, Tomas; Sandberg, Bengt; Strand, Sven-Erik; Tennvall, Jan

Book ID: 120614371
Publisher: Mary Ann Liebert
Year: 2005
Tongue: English
Weight: 147 KB
Volume: 20
Category: Article
ISSN: 1084-9785
DOI: 10.1089/cbr.2005.20.457

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II Study of Vincristine Sulfate Li

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative Therapy

✍ Kaplan, Lawrence D.; Deitcher, Steven R.; Silverman, Jeffrey A.; Morgan, Gareth 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 203 KB

The city of hope experience with novel t

The city of hope experience with novel transplant regimens that incorporate standard and escalated dose 90YTTRIUM ibritumomab tiuxetan (90Y-Zevalin®) radioimmunotherapy (RIT) for autologous stem cell transplantation (ASCT) in patients with B-cell non-Hodgkin’s lymphoma (NHL): targeted intensification without increased toxicity and elimination of total body irradiation (TBI)

✍ A. Nademanee; H. Fung; A. Molina; A. Krishnan; R. Rodriguez; L. Popplewell; R.T. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 56 KB